Clene Price Target Maintained With a $23.00/Share by EF Hutton
Clene Analyst Ratings
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Strategic Advancements and Robust Trial Design Drive Buy Rating for Clene
Benchmark Co. Sticks to Their Buy Rating for Clene (CLNN)
Clene Is Maintained at Buy by Canaccord Genuity
Clene Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Buy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene's CNM-Au8
Clene Analyst Ratings
EF Hutton Initiates Clene at Buy With $23 Price Target
EF Hutton Initiates Clene(CLNN.US) With Buy Rating, Announces Target Price $23
Clene Analyst Ratings
Buy Rating Justified for Clene Amidst Promising ALS Trial Results and Potential Accelerated FDA Approval
Clene Analyst Ratings
Canaccord Genuity Reiterates Buy on Clene, Maintains $94 Price Target
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
No Data
No Data